Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
37 hedge funds and large institutions have $17.3M invested in Carisma Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 42 closing their positions.
71% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $1.57M
13.04% more ownership
Funds ownership: 0.8% → 13.84% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $19.8M → $17.3M (-$2.52M)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
47% less funds holding
Funds holding: 70 → 37 (-33)
79% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TOTUOP
Trustees of The University of Pennsylvania
Philaldelphia,
Pennsylvania
|
+$20.8M |
| 2 |
TGA
TPG GP A
Fort Worth,
Texas
|
+$16M |
| 3 |
DCM
Deuterium Capital Management
Clearwater,
Florida
|
+$488K |
| 4 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$445K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$361K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$207K |
| 3 |
Morgan Stanley
New York
|
-$202K |
| 4 |
Jane Street
New York
|
-$174K |
| 5 |
Millennium Management
New York
|
-$153K |
CARM Hedge Fund Activity: Q1 2023 in Review
37 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2023, worth a combined $17.3M — down 13% from $19.8M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of CARM and 9 opened new positions — a net loss of 33 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Trustees of The University of Pennsylvania, opening a new position worth an estimated $20.8M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $361K sold.
- 37 institutional investors held Carisma Therapeutics (CARM) as of Q1 2023, down from 70 in Q4 2022.
- Funds reported $17.3M of Carisma Therapeutics stock for Q1 2023, down 13% quarter-over-quarter.
- 9 funds opened new Carisma Therapeutics positions in Q1 2023 and 42 closed out, a net change of -33 holders.
- The largest Carisma Therapeutics buyer in Q1 2023 was Trustees of The University of Pennsylvania, an estimated $20.8M added.
- The largest Carisma Therapeutics seller in Q1 2023 was Acadian Asset Management, an estimated $361K sold.
Based on aggregated 13F filings for Q1 2023.